AOLS (Aeolus Pharmaceuticals) ROE % Adjusted to Book Value: -6.27% (As of Jun. 2017)


What is Aeolus Pharmaceuticals ROE % Adjusted to Book Value?

Aeolus Pharmaceuticals AOLS ROE % Adjusted to Book Value is -6.27% as of Jun. 2017.

Aeolus Pharmaceuticals's ROE % for the quarter that ended in Jun. 2017 was -569.12%. Aeolus Pharmaceuticals's PB Ratio for the quarter that ended in Jun. 2017 was 90.82. Aeolus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2017 was -6.27%.

Aeolus Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Aeolus Pharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals ROE % Adjusted to Book Value Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Equity 0.00 -0.34 0.00 -33.46

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.16 -12.25 -12.02 -18.71 -6.27

AOLS vs RDGL, PCYN, YBAO: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aeolus Pharmaceuticals ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's ROE % Adjusted to Book Value falls into.


Aeolus Pharmaceuticals ROE % Adjusted to Book Value Calculation

Aeolus Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2016 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-302.81% / 9.05
=-33.46%

Aeolus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2017 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-569.12% / 90.82
=-6.27%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -6.27% mean?
Aeolus Pharmaceuticals (AOLS) has a ROE % Adjusted to Book Value of -6.27% as of Jun. 2017. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' ROE % Adjusted to Book Value too high?
Aeolus Pharmaceuticals' current ROE % Adjusted to Book Value is -6.27%.
How does Aeolus Pharmaceuticals' ROE % Adjusted to Book Value compare to RDGL and PCYN?
Aeolus Pharmaceuticals' ROE % Adjusted to Book Value of -6.27% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current ROE % Adjusted to Book Value is -6.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current ROE % Adjusted to Book Value of -6.27%. The current ROE % Adjusted to Book Value is -6.27%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current ROE % Adjusted to Book Value is -6.27% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.